Section Arrow
BBIO.NASDAQ
- BridgeBio Pharma
Quotes are at least 15-min delayed:2025/09/01 06:12 EDT
Regular Hours
Last
 51.76
-0.81 (-1.54%)
Day High 
52.845 
Prev. Close
52.57 
1-M High
52.6 
Volume 
3.00M 
Bid
50.75
Ask
52.25
Day Low
50.905 
Open
52.49 
1-M Low
42.0901 
Market Cap 
10.05B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 49.58 
20-SMA 48.82 
50-SMA 46.55 
52-W High 52.845 
52-W Low 21.72 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.13/-1.89
Enterprise Value
11.78B
Balance Sheet
Book Value Per Share
-9.35
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
9.30M
Operating Revenue Per Share
0.05
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CARMCarisma Therapeutics0.215-0.013-5.70%-- 
TNFATNF Pharmaceuticals Inc.0.0483-0.0133-21.59%-- 
ADAPAdaptimmune Therapeutics plc0.0589-0.01-14.51%-- 
SRPTSarepta Therapeutics18.2-0.14-0.76%15.76PE
OTLKOutlook Therapeutics0.8512-0.2388-21.91%0.58PE
Quotes are at least 15-min delayed:2025/09/01 06:12 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.